[go: up one dir, main page]

WO2007015270A2 - Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine - Google Patents

Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine Download PDF

Info

Publication number
WO2007015270A2
WO2007015270A2 PCT/IN2006/000274 IN2006000274W WO2007015270A2 WO 2007015270 A2 WO2007015270 A2 WO 2007015270A2 IN 2006000274 W IN2006000274 W IN 2006000274W WO 2007015270 A2 WO2007015270 A2 WO 2007015270A2
Authority
WO
WIPO (PCT)
Prior art keywords
controlled release
pharmaceutical composition
release pharmaceutical
composition according
group
Prior art date
Application number
PCT/IN2006/000274
Other languages
English (en)
Other versions
WO2007015270A3 (fr
Inventor
Avinash K. Velhal
Vineeth Raghavan
Suryakumar Jayanthi
Himadri Sen
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Priority to JP2008524679A priority Critical patent/JP5153629B2/ja
Priority to AU2006274565A priority patent/AU2006274565B2/en
Publication of WO2007015270A2 publication Critical patent/WO2007015270A2/fr
Publication of WO2007015270A3 publication Critical patent/WO2007015270A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a novel controlled release composition
  • a novel controlled release composition comprising a selective serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof.
  • Paroxetine disclosed in U.S. Pat. No. 4,007,196 is a selective serotonin reuptake inhibitor (SSRI) and is currently marketed worldwide for the treatment and/or prophylaxis of depression. Paroxetine is used in the form of the crystalline hemihydrate as disclosed in U.S. Pat. No. 4,721,723.
  • SSRI serotonin reuptake inhibitor
  • controlled release it is meant that the release of the active substance from the dosage form is modified to occur at a slower rate than that from the immediate release product, such as a conventional swallow tablet or capsule.
  • U.S. Pat. Nos. US 4,839,177 relates to a system for the controlled release of active substances, consisting of: (a) a deposit core comprising effective amount of the active substances and having defined geometric form, (b) a support-platform applied to said deposit core wherein the said deposit core contains, mixed with the active substance, at least one member selected from the group consisting of (a) 5-80% by weight of the total weight of the deposit core of a polymeric material having a high degree of swelling on contact with water or aqueous liquids and 90-10% by weight of the total weight of the deposit core of a gellable polymeric material, and (b) a single polymeric material having both swelling and gelling properties and other adjuvants able to provide the mixture with suitable characteristics for compression and for intake of water, and wherein said support platform consists of polymeric material insoluble in aqueous liquids and partially coating said deposit core.
  • U.S. Pat. No. 5,422,123 discloses a system for controlled release comprising of a deposit- core comprising an effective amount of the active substance and having defined geometric form, and a support-platform applied to said deposit-core, wherein said deposit-core contains at least the active substance, and at least one member selected from the group consisting of (1) a polymeric material which swells on contact with water or aqueous liquids and a gellable polymeric material wherein the ratio of the said swellable polymeric material to said gellable polymeric material is in the range 1:9 to 9:1, and (2) a single polymeric material having both swelling and gelling properties, and wherein the support-platform is an elastic support, applied to said deposit-core so that it partially covers the surface of the deposit-core and follows changes due to hydration of the deposit-core and is slowly soluble and/or slowly gellable in aqueous fluids.
  • the support- platform may comprise polymers such as hydroxypropylmethylcellulose, plasticizers such as a glyceride, binders such as polyvinylpyrrolidone, hydrophilic agents such as lactose and silica, and/or hydrophobic agents such as magnesium stearate and glycerides.
  • the polymer(s) typically make up 30 to 90% by weight of the support-platform, for example about 35 to 40%.
  • Plasticizer may make up at least 2% by weight of the support-platform, for example about 15 to 20%.
  • Binder(s), hydrophilic agent(s) and hydrophobic agent(s) typically total up to about 50% by weight of the support-platform, for example about 40 to 50%.
  • U.S. Pat. No. 6,482,440 relates to pharmaceutically active materials comprising specific antidepressant compounds contained in microp articles formulated so as to release the antidepressant compounds over an extended period of time.
  • PCT Appl. No. WO 2005/034954 relates to stable pharmaceutical compositions of paroxetine comprising the drug, microcrystalline cellulose, at least one modified release polymer and one or more additional pharmaceutical inert excipients, wherein the composition is prepared by wet granulation. Compressed tablets are further coated with enteric polymers and further with nonfunctional film coating polymers.
  • U.S. Pat. Appl. No. 2002/0090394 discloses a controlled and delayed release formulation containing a selective serotonin reuptake inhibitor such as paroxetine. Release of the drag is delayed by pH sensitive coat using hydroxypropylmethylcellulose phthalate, cellulose acetate phthalate, and Eudragit etc. followed by controlled release. This results in reducing the incidence of nausea and vomiting associated with the administration of paroxetine by releasing the drug predominantly in the small intestine.
  • This patent application describes a novel controlled release formulation of a selective serotonin reuptake inhibitor or a pharmaceutically acceptable salt thereof comprising a controlled release matrix formulation.
  • the present invention provides a novel controlled release composition comprising a SSRI or a pharmaceutically acceptable salt thereof.
  • the present invention provides the use for treating and/or preventing the disorders by administering an effective and/or a prophylactic amount of novel controlled release composition comprising SSRI or a pharmaceutically acceptable salt thereof, to an individual in need thereof.
  • novel controlled release compositions of SSRI or a pharmaceutically acceptable salts thereof comprising: a) a core comprising the active ingredient; one or more controlled release polymer(s) and pharmaceutically acceptable excipients; and optionally b) a coating comprising one or more controlled release polymer(s).
  • novel controlled release composition comprising SSRI or a pharmaceutically acceptable salt thereof for treating and/or preventing the disorders.
  • the present invention provides a novel controlled release composition of SSRI or a pharmaceutically acceptable salts thereof.
  • Selective serotonin reuptake inhibitors include sertraline, fluoxetine, fluvoxamine, citalopram, escitalopram and paroxetine.
  • SSRI used in the present invention is suitably in the form of the free base or a pharmaceutically acceptable salt thereof.
  • Paroxetine is used preferably in the form of the hydrochloride hemihydrate.
  • SSRI in the form of a controlled release composition can be used to treat and prevent the following disorders: Alcoholism, Anxiety, Depression, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymia, Substance Abuse.
  • the preparation comprises: a) a core comprising the active ingredient; one or more controlled release polymer(s) and pharmaceutically acceptable excipients; and optionally b) a coating comprising one or more controlled release polymer(s).
  • Controlled release polymers used in the core and coating of this composition include one or more of cellulose derivatives, alginic acids derivatives, polymethacrylates, polysaccharides, alkylene oxides, hydrogenated vegetable oil and the like.
  • cellulose derivatives include hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), methylcellulose, carboxy methylcellulose, ethyl cellulose and hydroxy ethyl cellulose.
  • HPC hydroxypropyl cellulose
  • HPMC hydroxypropyl methylcellulose
  • Alginic acid derivatives as used herein include alginic acid and its physiologically acceptable salts such as those of sodium, potassium, calcium, and the like.
  • polymethacrylates are various types of methacrylic acid derivatives and copolymers thereof such as various grades available under the trade name of Eudragit®.
  • polysaccharides include chitosan, gellan, xanthan gum and the like.
  • alkylene oxide include polyethylene oxide.
  • Controlled release polymers used in the core may range from about 10-50% w/w in the core and from about 1-15% w/w in the coating.
  • HPMC is cellulose ether, and is widely used as controlled release polymer. It is commercially available as Methocel® in various grades.
  • HPMC of low viscosity grades examples include Methocel E-5 LV, Methocel E- 15 LV, Methocel E-50 LV, Methocel K-IOO LV CR Premium and Methocel F-50 LV.
  • HPMC of medium viscosity grade examples include Methocel E4M, Methocel K4MCR, Methocel Kl 5M Premium, Methocel KlOO M Premium and Methocel F4M.
  • Eudragit L-30 D-55 is a 30% aqueous dispersion soluble in intestinal fluids from pH 5.5.
  • compositions comprise diluents, disintegrants, binders and lubricants.
  • Diluents referred to in the present invention include one or more selected from mannitol, dextrose, xylitol, sorbitol, sucrose, microcrystalline cellulose, calcium carbonate, calcium phosphate dibasic, calcium phosphate tribasic, calcium sulfate, lactose, starches, vinyl polymers and the like known to a person skilled in the art.
  • Disintegrants referred to in the present invention include one ore more of microcrystalline cellulose, croscarmellose sodium, crospovidone, carboxymethyl starch sodium, sodium starch glycolate, and the like.
  • Binders referred to in the present invention include one or more selected from those well known in the art to a person skilled in the art, as exemplified can be celluloses such as hydroxypropyl cellulose, hydroxy ethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose or mixtures thereof, acrylates, methacrylates, povidone and other materials known to have cohesive and desirable binding properties.
  • Lubricants referred to in the present invention include one or more selected from those well known in the art, as exemplified can be stearates, hydrogenated vegetable oil, sodium stearyl fumarate, talc, colloidal silicon dioxide, palmitic acid, carnauba wax, glyceryl monostearate, microcrystalline wax, polyoxyethylene monostearates, fats and stearic acid or mixtures thereof.
  • Novel controlled release pharmaceutical compositions comprising core may be prepared by wet granulation method using purified water.
  • the selective serotonin reuptake inhibitor is mixed with one or more controlled release polymer(s) and pharmaceutically acceptable excipients and granulate with purified water. Dry the granules and mix with lubricants and compress into core tablets.
  • These core tablets are optionally coated with a coating composition comprising one or more controlled release polymer(s) and other coating aids like plasticizers and film formers.
  • plasticizers include one or more of polyethylene glycol, triethyl citrate, triacetin, diethyl phthalate, dibutyl stearate, dibutyl sebacate, oleic acid, alcohol, mineral oil, castor oil, lanolin, petrolatum, propylene glycol, glycerol and the like.
  • film forming polymers include one or more of ethyl cellulose, HPMC, HPC, methylcellulose, hydroxyethyl cellulose; waxes such as polyethylene glycol.
  • the coating may be performed by conventional means using commercially available, ready-to-coat preparations, sold under various brand names such as various grades of Opadry®, Surelease® Dispersions or mixtures thereof and the like.
  • Opadry® is a film coating system comprising HPMC, polyethylene glycol and titanium dioxide.
  • Surelease® dispersion is a controlled release film coating system comprising ethyl cellulose, ammonium hydroxide, dibutyl sebacate, oleic acid and anhydrous colloidal silica.
  • Coating dispersion is prepared by using one or more controlled release polymer(s) 5 described in the above examples; or mixing one or more coating dispersion(s) and optionally, coat tablets to a required build-up using conventional coating techniques.
  • Dissolution profile of these novel controlled release compositions of Paroxetine is compared with Paroxetine controlled release tablets available in the market under the 10 brand name Paxil CR. Dissolution study is conducted using USP dissolution tester and the results are as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique à libération contrôlée à base d'un inhibiteur sélectif de la recapture de la sérotonine. Cette composition comprend principalement un noyau contenant le principe actif, un ou plusieurs polymères à libération contrôlée et un ou plusieurs excipients de qualité pharmaceutique. La composition comporte éventuellement une revêtement à base d'un ou plusieurs polymères à libération contrôlée. La composition est préparée selon un procédé consistant à mélanger le principe actif avec un ou plusieurs polymères à libération contrôlée et un ou plusieurs excipients de qualité pharmaceutique. Ensuite, le mélange est soumis à une granulation, séché, lubrifié et transformé en comprimés. La composition est utilisée dans la fabrication d'un médicament, pour le traitement et/ou la prévention de troubles. Le principe actif est libéré en 2 à 8 heures environ, 10 à 25 % environ du principe actif étant libéré in vitro en 2 heures dans une solution de HCl 0,1N, selon une étude de dissolution menée avec 750 ml d'un milieu de dissolution, un testeur de dissolution USP et un agitateur à ailettes à 150 tours/minute. Environ 20 à 55 %, 50 à 75 % et 70 à 95 % du principe actif est libéré in vitro en 4, 6 et 8 heures, respectivement, dans un tampon Tris à pH 7,5, selon une étude de dissolution menée avec 1000 ml d'un milieu de dissolution, un testeur de dissolution USP et un agitateur à ailettes à 150 tours/minute.
PCT/IN2006/000274 2005-08-02 2006-08-01 Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine WO2007015270A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008524679A JP5153629B2 (ja) 2005-08-02 2006-08-01 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
AU2006274565A AU2006274565B2 (en) 2005-08-02 2006-08-01 Novel controlled release compositions of selective serotonin reuptake inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN696/KOL/2005 2005-08-02
IN696KO2005 2005-08-02

Publications (2)

Publication Number Publication Date
WO2007015270A2 true WO2007015270A2 (fr) 2007-02-08
WO2007015270A3 WO2007015270A3 (fr) 2007-04-19

Family

ID=37392535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000274 WO2007015270A2 (fr) 2005-08-02 2006-08-01 Nouvelles compositions a liberation controlee a base d'inhibiteurs selectifs de la recapture de la serotonine

Country Status (3)

Country Link
JP (1) JP5153629B2 (fr)
AU (1) AU2006274565B2 (fr)
WO (1) WO2007015270A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123922A1 (fr) 2011-03-17 2012-09-20 Lupin Limited Compositions pharmaceutiques à libération contrôlée d'un inhibiteur sélectif de la recapture de sérotonine
EP2727915A1 (fr) 2007-09-13 2014-05-07 Concert Pharmaceuticals Inc. Synthèse de catéchols deutériés et benzo[d] [1,3]dioxoles et leurs dérivés
CN112494445A (zh) * 2020-12-11 2021-03-16 丽珠集团丽珠制药厂 一种马来酸氟伏沙明组合物及其制备方法
WO2021256844A1 (fr) * 2020-06-15 2021-12-23 환인제약 주식회사 Composition pharmaceutique
CN117503741A (zh) * 2023-11-06 2024-02-06 苏州盛达药业有限公司 一种缓释型氟伏沙明及其制备方法
RU2814336C1 (ru) * 2022-04-20 2024-02-28 Асена Фармасьютик Сас Высокодозная композиция транексамовой кислоты и способы ее получения

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2769872A1 (fr) * 2009-08-24 2011-03-03 H. Lundbeck A/S Nouvelles compositions de 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US6168805B1 (en) * 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
AU782059B2 (en) * 1999-05-20 2005-06-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
DK200100341A (da) * 2001-03-02 2002-09-03 Gea Farmaceutisk Fabrik As Fremgangsmåde til fremstilling af farmaceutiske tabletter indeholdende paroxetinhydrochlorid-anhydrat
CA2415154C (fr) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Preparations a liberation modifiee contenant des inhibiteurs selectifs de la recapture de la serotonine

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727915A1 (fr) 2007-09-13 2014-05-07 Concert Pharmaceuticals Inc. Synthèse de catéchols deutériés et benzo[d] [1,3]dioxoles et leurs dérivés
WO2012123922A1 (fr) 2011-03-17 2012-09-20 Lupin Limited Compositions pharmaceutiques à libération contrôlée d'un inhibiteur sélectif de la recapture de sérotonine
WO2021256844A1 (fr) * 2020-06-15 2021-12-23 환인제약 주식회사 Composition pharmaceutique
KR20210155447A (ko) * 2020-06-15 2021-12-23 환인제약 주식회사 의약 조성물
KR102441089B1 (ko) 2020-06-15 2022-09-07 환인제약 주식회사 의약 조성물
CN112494445A (zh) * 2020-12-11 2021-03-16 丽珠集团丽珠制药厂 一种马来酸氟伏沙明组合物及其制备方法
RU2814336C1 (ru) * 2022-04-20 2024-02-28 Асена Фармасьютик Сас Высокодозная композиция транексамовой кислоты и способы ее получения
CN117503741A (zh) * 2023-11-06 2024-02-06 苏州盛达药业有限公司 一种缓释型氟伏沙明及其制备方法

Also Published As

Publication number Publication date
JP5153629B2 (ja) 2013-02-27
AU2006274565A1 (en) 2007-02-08
JP2009503057A (ja) 2009-01-29
AU2006274565B2 (en) 2012-05-17
WO2007015270A3 (fr) 2007-04-19

Similar Documents

Publication Publication Date Title
AU760006B2 (en) Method for making granules with masked taste and instant release of the active particle
CA2704646C (fr) Comprimes a liberation prolongee contenant de l'hydromorphone
TWI469781B (zh) 黏結劑於製造貯存安定性調合物上之用途
WO2010138439A1 (fr) Formulations d'inhibiteur de réabsorption sélective de sérotonine à libération contrôlée et multiples particules
JP5420590B2 (ja) ｐＨ非依存延長放出性医薬組成物
JPH05201866A (ja) 配合製剤
AU2006274565B2 (en) Novel controlled release compositions of selective serotonin reuptake inhibitors
MX2014007331A (es) Sistema de multiunidades de granulos de liberacion inmediata.
EP2740471B1 (fr) Composition pharmaceutique orale comprenant le dabigatran etexilate
JP2012515757A (ja) トリメタジジンの放出調節固形薬剤組成物及びその製造方法
WO2007070840A2 (fr) Formulations pharmaceutiques d'escitalopram modifiees et a liberation pulsatile
US20140010883A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
JP2001522882A (ja) ザファルカストを含有する医薬品組成物
EP1512394A1 (fr) Composition universelle à libération controlée comprenant du chitosane
US20090169617A1 (en) Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
WO2003011256A1 (fr) Composition pharmaceutique d'agent procinetique a liberation orale controlee
US8980318B2 (en) Neramexane multiple unit dosage form
WO2008015530A2 (fr) Formulation orale solide stable d'un medicament acide labile
US20090130206A1 (en) Controlled Release Compositions of an Antidepressant Agent
WO2006111853A2 (fr) Formes posologiques solides stables d'un medicament labile en milieu acide
WO2005034954A2 (fr) Compositions pharmaceutiques de paroxetine
WO2006016829A1 (fr) Formulation à libération contrôlée comprenant de l’hydrochlorure de tamsulosine
HK1174274A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2008524679

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006274565

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006274565

Country of ref document: AU

Date of ref document: 20060801

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006274565

Country of ref document: AU

122 Ep: pct application non-entry in european phase

Ref document number: 06780554

Country of ref document: EP

Kind code of ref document: A2